您的位置: 专家智库 > >

匡韦陆

作品数:3 被引量:15H指数:1
供职机构:中南大学湘雅医院更多>>
发文基金:湖南省自然科学基金更多>>
相关领域:医药卫生更多>>

文献类型

  • 3篇中文期刊文章

领域

  • 3篇医药卫生

主题

  • 1篇调强
  • 1篇调强放射
  • 1篇调强放射治疗
  • 1篇乳腺
  • 1篇乳腺癌
  • 1篇乳腺肿
  • 1篇乳腺肿瘤
  • 1篇人宫颈癌
  • 1篇人宫颈癌细胞
  • 1篇肿瘤
  • 1篇左侧
  • 1篇左侧乳腺癌
  • 1篇细胞
  • 1篇腺癌
  • 1篇腺肿瘤
  • 1篇基因
  • 1篇剂量学
  • 1篇剂量学比较
  • 1篇宫颈
  • 1篇宫颈癌

机构

  • 3篇中南大学

作者

  • 3篇匡韦陆
  • 2篇申良方
  • 2篇欧阳淑玉
  • 2篇周琴
  • 1篇贺理礼
  • 1篇贺礼理
  • 1篇谢小雪
  • 1篇周略
  • 1篇刘铮铮

传媒

  • 2篇中南大学学报...
  • 1篇Chines...

年份

  • 1篇2019
  • 1篇2013
  • 1篇2009
3 条 记 录,以下是 1-3
排序方式:
腺病毒E1A基因对人宫颈癌细胞体外增殖抑制的实验研究
2009年
目的:探讨聚已烯亚胺-四氧化三铁(PEI-Fe3O4)纳米粒E1A基因对人宫颈癌细胞体外增殖的抑制作用及其作用机制,为宫颈癌E1A基因治疗的可行性提供实验依据。方法:E1A基因经PEI-Fe3O4纳米粒载体介导转染人宫颈癌细胞(Hela细胞),用细胞计数法测绘生长曲线、计算倍增时间及软琼脂集落形成数目,观察E1A基因对该细胞系体外生长的影响。采用RT-PCR和Western印迹检测E1A基因在宫颈癌细胞中的表达及对HER-2/neu基因表达的影响。结果:转染E1A基因的人宫颈癌细胞系生长缓慢,倍增时间延长,是转染空载体组的1.53倍,是Hela细胞组的1.58倍;未经转染的Hela细胞系、转染空载体纳米粒的Hela细胞系(Hela-vect)及转染E1A基因的Hela细胞系(Hela-E1A),细胞集落形成率分别为30.48%,28.32%和6.62%,转染E1A基因组(Hela-vect)明显低于Hela和Hela-vect组(均P<0.05)。与Hela及Hela-vect组的集落形成率相比,Hela-E1A组集落形成抑制率分别为78.28%和76.62%。RT-PCR和Western印迹结果显示,E1A基因能在Hela细胞中稳定表达,且显著降低了HER-2/neu在宫颈癌细胞中的mRNA和蛋白表达水平。结论:PEI-Fe3O4纳米粒E1A基因能够明显抑制人宫颈癌细胞的生长,其作用机制可能与E1A抑制HER-2/neu基因的表达有关。
欧阳红匡韦陆周琴贺理礼周略欧阳淑玉申良方
关键词:人宫颈癌细胞E1A基因HER-2/NEU基因
左侧乳腺癌两种调强放射治疗计划剂量学比较被引量:15
2013年
目的:比较左侧乳腺癌保乳术后两种调强放疗计划的剂量学差异,评价两种计划的剂量学特点,为临床治疗方法的优选提供依据。方法:选择8例左侧乳腺癌保乳术后患者,利用三维治疗计划系统为每例患者分别设计调强放射治疗计划(IMRT)和混合调强放射治疗计划(Hybrid IMRT)。在剂量体积直方图(DVH)上比较靶区和正常组织器官照射剂量、不均匀指数和适形指数。结果:在具有相同覆盖率(V95%)的情况下,Hybrid IMRT的靶区剂量均匀度优于IMRT。两种计划的适形指数,V105%,V110%,最大剂量(Dmax),最小剂量(Dmin),平均剂量(Dmean)均无显著差异。HybridIMRT和IMRT相比,同侧肺接受13Gy的体积(V13)由27.66%降至20.7%,对侧肺V5由8.01%降至2.25%;心脏V10,V20分别由35.23%,16.77%降至19.22%,10.6%;对侧乳腺V5,V10分别由35%,10.39%降至20.38%,5.7%,差异均具有统计学意义(P<0.05);而对于同侧肺V30,V40及心脏V40,分别升高了1.28%,1.48%,2.48%,差异有统计学意义(P<0.05)。结论:在乳腺癌患者放疗体位重复性不太好和(或)摆位精确性不能保证的情况下,混合调强放疗技术是更好的选择。
欧阳淑玉贺礼理谢小雪周琴匡韦陆申良方
关键词:乳腺肿瘤调强放射治疗
Downregulation of iASPP Expression Suppresses Proliferation, Invasion and Increases Chemosensitivity to Paclitaxel of Head and Neck Squamous Cell Carcinoma In Vitro
2019年
Objective Our previous study has revealed that iASPP is elevated in human head and neck squamous cell carcinoma(HNSCC)and iASPP overexpression signifcantly correlates with tumor malignant progression and poor survival of HNSCC.This study investigated the function of iASPP playing in proliferation and invasion of HNSCC in vitro.Methods HNSCC cell line Tu686 transfected with Lentiviral vector-mediated iASPP-specific shRNA and control shRNA were named the shRNA-iASPP group and shRNA-NC group,respectively.The non-infected Tu686 cells were named the CON group.CCK-8 assay,flow cytometry,transwell invasion assay were performed to detect the effects of iASPP inhibition in vitro.Results Our results demonstrated that the proliferation of shRNA-iASPP cells at the time of 72 h(F=32.459,P=0.000),96 h(F=51.407,P=0.000),120 h(F=35.125,P=0.000)post-transfection,was significantly lower than that of shRNANC cells and CON cells.The apoptosis ratio of shRNA-iASPP cells was 9.42%±0.39%(F=299.490,P=0.000),which was significantly higher than that of CON cells(2.80%±0.42%)and shRNA-NC cells(3.18%±0.28%).The percentage of shRNA-iASPP cells in G0/G1 phase was 74.65%±1.09%(F=388.901,P=0.000),which was strikingly increased,compared with that of CON cells(55.19%±1.02%)and shRNA-NC cells(54.62%±0.88%).The number of invading cells was 56±4 in the shRNA-iASPP group(F=84.965,P=0.000),which decreased significantly,compared with the CON group(111±3)and the shRNA-NC group(105±8).The survival rate of shRNA-iASPP cells administrated with paclitaxel was highly decreased,compared with CON cells and shRNA-NC cells(F=634.841,P=0.000).Conclusion These results suggest iASPP may play an important role in progression and aggressive behavior of HNSCC and may be an efficient chemotherapeutic target for the treatment of HNSCC.
刘铮铮匡韦陆曾文静肖健云田勇泉
关键词:SQUAMOUSIASPPCHEMOSENSITIVITYPACLITAXEL
共1页<1>
聚类工具0